267 related articles for article (PubMed ID: 29158360)
21. Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.
Marsilio S; Khiabanian H; Fabbri G; Vergani S; Scuoppo C; Montserrat E; Shpall EJ; Hadigol M; Marin P; Rai KR; Rabadan R; Devereux S; Pasqualucci L; Chiorazzi N
Leukemia; 2018 Apr; 32(4):1041-1044. PubMed ID: 29203856
[No Abstract] [Full Text] [Related]
22. Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.
Venkatesan AM; Vyas R; Gramann AK; Dresser K; Gujja S; Bhatnagar S; Chhangawala S; Gomes CBF; Xi HS; Lian CG; Houvras Y; Edwards YJK; Deng A; Green M; Ceol CJ
J Clin Invest; 2018 Jan; 128(1):294-308. PubMed ID: 29202482
[TBL] [Abstract][Full Text] [Related]
23. Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma.
Butler MJ; Aguiar RCT
Trends Cancer; 2017 Dec; 3(12):871-882. PubMed ID: 29198442
[TBL] [Abstract][Full Text] [Related]
24. Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma.
van der Meeren LE; Visser L; Diepstra A; Nijland M; van den Berg A; Kluin PM
Histopathology; 2018 Apr; 72(5):886-888. PubMed ID: 29194719
[No Abstract] [Full Text] [Related]
25. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
26. First targeted therapy in multiple myeloma.
Kortüm KM; Einsele H
Blood; 2017 Nov; 130(22):2359-2360. PubMed ID: 29191974
[No Abstract] [Full Text] [Related]
27. O-GlcNAcylation is required for B cell homeostasis and antibody responses.
Wu JL; Chiang MF; Hsu PH; Tsai DY; Hung KH; Wang YH; Angata T; Lin KI
Nat Commun; 2017 Nov; 8(1):1854. PubMed ID: 29187734
[TBL] [Abstract][Full Text] [Related]
28. CD4+ T cell-mediated cytotoxicity is associated with MHC class II expression on malignant CD19+ B cells in diffuse large B cell lymphoma.
Zhou Y; Zha J; Lin Z; Fang Z; Zeng H; Zhao J; Luo Y; Li Z; Xu B
Exp Cell Res; 2018 Jan; 362(2):287-292. PubMed ID: 29174982
[TBL] [Abstract][Full Text] [Related]
29. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
Schick M; Habringer S; Nilsson JA; Keller U
Br J Haematol; 2017 Dec; 179(5):724-738. PubMed ID: 29171017
[TBL] [Abstract][Full Text] [Related]
30. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles.
Hellmuth JC; Louissaint A; Szczepanowski M; Haebe S; Pastore A; Alig S; Staiger AM; Hartmann S; Kridel R; Ducar MD; Koch P; Dreyling M; Hansmann ML; Ott G; Rosenwald A; Gascoyne RD; Weinstock DM; Hiddemann W; Klapper W; Weigert O
Blood; 2018 Oct; 132(16):1695-1702. PubMed ID: 30126979
[TBL] [Abstract][Full Text] [Related]
31. Critical influences on the pathogenesis of follicular lymphoma.
Küppers R; Stevenson FK
Blood; 2018 May; 131(21):2297-2306. PubMed ID: 29666116
[TBL] [Abstract][Full Text] [Related]
32. From genetics to the clinic: a translational perspective on follicular lymphoma.
Huet S; Sujobert P; Salles G
Nat Rev Cancer; 2018 Apr; 18(4):224-239. PubMed ID: 29422597
[TBL] [Abstract][Full Text] [Related]
33. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
[TBL] [Abstract][Full Text] [Related]
34. Follicular lymphoma.
Carbone A; Roulland S; Gloghini A; Younes A; von Keudell G; López-Guillermo A; Fitzgibbon J
Nat Rev Dis Primers; 2019 Dec; 5(1):83. PubMed ID: 31831752
[TBL] [Abstract][Full Text] [Related]
35. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.
Béguelin W; Teater M; Meydan C; Hoehn KB; Phillip JM; Soshnev AA; Venturutti L; Rivas MA; Calvo-Fernández MT; Gutierrez J; Camarillo JM; Takata K; Tarte K; Kelleher NL; Steidl C; Mason CE; Elemento O; Allis CD; Kleinstein SH; Melnick AM
Cancer Cell; 2020 May; 37(5):655-673.e11. PubMed ID: 32396861
[TBL] [Abstract][Full Text] [Related]
36. Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.
Meyer SN; Scuoppo C; Vlasevska S; Bal E; Holmes AB; Holloman M; Garcia-Ibanez L; Nataraj S; Duval R; Vantrimpont T; Basso K; Brooks N; Dalla-Favera R; Pasqualucci L
Immunity; 2019 Sep; 51(3):535-547.e9. PubMed ID: 31519498
[TBL] [Abstract][Full Text] [Related]
37. Genetics of diffuse large B-cell lymphoma.
Pasqualucci L; Dalla-Favera R
Blood; 2018 May; 131(21):2307-2319. PubMed ID: 29666115
[TBL] [Abstract][Full Text] [Related]
38. M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
Lockmer S; Ren W; Brodtkorb M; Østenstad B; Wahlin BE; Pan-Hammarström Q; Kimby E
Br J Haematol; 2020 Jan; 188(2):259-267. PubMed ID: 31423576
[TBL] [Abstract][Full Text] [Related]
39. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
40. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
